Collegium Pharmaceutical, Inc. announced that effective May 24, 2024, Joe Ciaffoni will step down as Chief Executive Officer (CEO) of the Company. Mr. Ciaffoni will serve as a member of the Board of Directors of the Company until the upcoming 2024 Annual Meeting of Shareholders and will not stand for re-election at the meeting. To ensure a seamless transition, Michael Heffernan, founder, former CEO and Chairman of the Board will serve as Interim CEO until a new CEO is appointed by the Board of Directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.14 USD | +2.19% | -3.24% | +7.67% |
May. 13 | Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program | MT |
May. 10 | Needham Downgrades Collegium Pharmaceutical to Hold From Buy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.67% | 1.08B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- COLL Stock
- News Collegium Pharmaceutical, Inc.
- Collegium Announces CEO Transition